{
  "ticker": "BOD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971511",
  "id": "02971511",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250722",
  "time": "1554",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0zjnqwklysd.pdf",
  "summary": "**Quarterly Report (Appendix 4C) Summary**  \n\n- **Net cash from operating activities**: $858k (up $816k from Q3 FY2025).  \n- **Receipts from customers**: $388k (up 5% QoQ, 326% YoY).  \n- **R&D tax incentive received**: $678k (related to FY24).  \n- **Biortica funding**: $255k received to partially cover operating costs.  \n- **DOCA status**: Extended to 7 August 2025 (further extensions possible); EGM expected by 30 September 2025.  \n- **Company remains suspended** under DOCA administration.  \n\n**No material trading or capital markets catalysts identified** (pending DOCA completion and shareholder approvals).",
  "usage": {
    "prompt_tokens": 1362,
    "completion_tokens": 164,
    "total_tokens": 1526,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T06:04:18.384947"
}